FLT3LG and lymphoma: We next tested the effect of NDV-killed tumor cells on human monocyte-derived DCs (Supplementary Fig. 2b), as well as on peripheral blood DCs from lymphoma patients treated with Flt3L, whose proportion of cDCs (as well as pDCs) is significantly increased post Flt3L (Fig. 2b and Supplementary Fig. 2c, study NCT01976585).